Search

Your search keyword '"Vink, G.R. (G. R.)"' showing total 2 results
Start Over Author "Vink, G.R. (G. R.)"
2 results on '"Vink, G.R. (G. R.)"'

1. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study

Author

van den Berg, I. (I.), van de Weerd, S. (S.), Roodhart, J.M. (Jeanine), Vink, G.R. (G. R.), Coebergh van den Braak, R.R.J. (Robert), Jimenez, C.R. (C. R.), Elias, S.G. (Sjoerd), van Vliet, D. (D.), Koelink, M. (M.), Hong, E. (E.), Grevenstein, H.M.U. (Helma) van, Oijen, M.G.H. (Martijn) van, Beets-Tan, R.G. (Regina), Van Krieken, J.H. (J. Han), IJzermans, J.N.M. (Jan), Medema, J.P. (Jan Paul), Koopman, M. (Miriam), van den Berg, I. (I.), van de Weerd, S. (S.), Roodhart, J.M. (Jeanine), Vink, G.R. (G. R.), Coebergh van den Braak, R.R.J. (Robert), Jimenez, C.R. (C. R.), Elias, S.G. (Sjoerd), van Vliet, D. (D.), Koelink, M. (M.), Hong, E. (E.), Grevenstein, H.M.U. (Helma) van, Oijen, M.G.H. (Martijn) van, Beets-Tan, R.G. (Regina), Van Krieken, J.H. (J. Han), IJzermans, J.N.M. (Jan), Medema, J.P. (Jan Paul), and Koopman, M. (Miriam)

Abstract

BACKGROUND: It is estimated that around 15-30% of patients with early stage colon cancer benefit from adjuvant chemotherapy. We are currently not capable of upfront selection of patients who benefit from chemotherapy, which indicates the need for additional predictive markers for response to chemotherapy. It has been shown that the consensus molecular subtypes (CMSs), defined by RNA-profiling, have prognostic and/or predictive value. Due to postoperative timing of chemotherapy in current guidelines, tumor response to chemotherapy per CMS is not known, which makes the differentiation between the prognostic and predictive value impossible. Therefore, we propose to assess the tumor response per CMS in the neoadjuvant chemotherapy setting. This will provide us with clear data on the predictive value for chemotherapy response of the CMSs. METHODS: In this prospective, single arm, multicenter intervention study, 262 patients with resectable microsatellite stable cT3-4NxM0 colon cancer will be treated with two courses of neoadjuvant and two courses of adjuvant capecitabine and oxaliplatin. The primary endpoint is the pathological tumor response to neoadjuvant chemotherapy per CMS. Secondary endpoints are radiological tumor response, the prognostic value of these responses for recurrence free survival and overall survival and the differences in CMS classification of the same tumor before and after neoadjuvant chemotherapy. The study is scheduled to be performed in 8-10 Dutch hospitals. T

Published
2020
Full Text
View/download PDF

2. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative

Author

Coebergh van den Braak, R.R.J. (Robert), van Rijssen, L.B. (Lennart B.), van Kleef, J.J. (J. J.), Vink, G.R. (G. R.), Berbee, M. (M.), van Berge Henegouwen, M.I., Bloemendal, H.J. (Haiko), Bruno, M.J. (Marco), Burgmans, M.C. (M. C.), Busch, O.R.C. (Olivier), Coene, P-P. (Peter Paul), Coupé, V.M.H. (Veerle), Dekker, J.W.T. (Jan Willem), Eijck, C.H.J. (Casper) van, Elferink, M.A.G. (Marloes), Erdkamp, F.L.G. (Frans ), Grevenstein, H.M.U. (Helma) van, Groot, J.W.B. (Jan Willem) de, Grieken, N.C.T. (Nicole), Hingh, I.H.J.T. (Ignace) de, Hulshof, M.C.C.M. (Maarten), IJzermans, J.N.M. (Jan), Kwakkenbos, L. (L.), Lemmens, V.E.P.P. (Valery), Los, M., Meijer, C.J.L.M. (Chris), Molenaar, I.Q. (I. Quintus), Nieuwenhuijzen, G.A.P. (Gerard), de Noo, M.E. (M. E.), Poll-Franse, L.V. (Lonneke) van de, Punt, C.J.A. (Cornelis), Rietbroek, R.C. (Ron), Roeloffzen, W.W.H. (W. W.H.), Rozema, T. (Tom), Ruurda, J.P. (Jelle), Sandick, J.W. (J.) van, Schiphorst, A.H.W. (A. H.W.), Schipper, H. (H.), Siersema, P.D. (Peter), Slingerland, M. (Marije), Sommeijer, D.W. (D. W.), Spaander, M.C.W. (Manon), Sprangers, M.A.G. (Mirjam), Stockmann, H.B.A.C. (Hein), Strijker, M. (M.), Tienhoven, G. (Geertjan) van, Timmermans, L.M. (L. M.), Tjin-a-Ton, M.L.R. (M. L.R.), Velden, A.M.T. van der, Verhaar, M.J. (M. J.), Verkooijen, H.M. (Helena M.), Vles, W., de Vos-Geelen, J. (Judith), Wilmink, J.W. (Johanna), Zimmerman, D.D.E. (David), Oijen, M.G.H. (Martijn) van, Koopman, M. (Miriam), Besselink, M.G. (Marc), Laarhoven, H.W.M. (Hanneke) van, Coebergh van den Braak, R.R.J. (Robert), van Rijssen, L.B. (Lennart B.), van Kleef, J.J. (J. J.), Vink, G.R. (G. R.), Berbee, M. (M.), van Berge Henegouwen, M.I., Bloemendal, H.J. (Haiko), Bruno, M.J. (Marco), Burgmans, M.C. (M. C.), Busch, O.R.C. (Olivier), Coene, P-P. (Peter Paul), Coupé, V.M.H. (Veerle), Dekker, J.W.T. (Jan Willem), Eijck, C.H.J. (Casper) van, Elferink, M.A.G. (Marloes), Erdkamp, F.L.G. (Frans ), Grevenstein, H.M.U. (Helma) van, Groot, J.W.B. (Jan Willem) de, Grieken, N.C.T. (Nicole), Hingh, I.H.J.T. (Ignace) de, Hulshof, M.C.C.M. (Maarten), IJzermans, J.N.M. (Jan), Kwakkenbos, L. (L.), Lemmens, V.E.P.P. (Valery), Los, M., Meijer, C.J.L.M. (Chris), Molenaar, I.Q. (I. Quintus), Nieuwenhuijzen, G.A.P. (Gerard), de Noo, M.E. (M. E.), Poll-Franse, L.V. (Lonneke) van de, Punt, C.J.A. (Cornelis), Rietbroek, R.C. (Ron), Roeloffzen, W.W.H. (W. W.H.), Rozema, T. (Tom), Ruurda, J.P. (Jelle), Sandick, J.W. (J.) van, Schiphorst, A.H.W. (A. H.W.), Schipper, H. (H.), Siersema, P.D. (Peter), Slingerland, M. (Marije), Sommeijer, D.W. (D. W.), Spaander, M.C.W. (Manon), Sprangers, M.A.G. (Mirjam), Stockmann, H.B.A.C. (Hein), Strijker, M. (M.), Tienhoven, G. (Geertjan) van, Timmermans, L.M. (L. M.), Tjin-a-Ton, M.L.R. (M. L.R.), Velden, A.M.T. van der, Verhaar, M.J. (M. J.), Verkooijen, H.M. (Helena M.), Vles, W., de Vos-Geelen, J. (Judith), Wilmink, J.W. (Johanna), Zimmerman, D.D.E. (David), Oijen, M.G.H. (Martijn) van, Koopman, M. (Miriam), Besselink, M.G. (Marc), and Laarhoven, H.W.M. (Hanneke) van

Abstract

Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients. Material and methods: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future. Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing. Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With t

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results